1,660
+1.72%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sawai Group Holdings Co
Its shares trade on Tokyo Stock Exchange under the ticker 4887.T. It has been listed since 1 April 2021. In the fiscal year to 31 March 2026, it reported revenue of ¥201.68bn and net income of ¥10.44bn. At that date it held total assets of ¥359.92bn and shareholders' equity of ¥178.56bn.
SAWAI GROUP HOLDINGS Co., Ltd. engages in medical and healthcare-related businesses. The company is headquartered in Osaka, Osaka-Fu. The company went IPO on 2021-04-01. The firm operates in two segments. The Japan segment is engaged in medical and healthcare-related businesses such as manufacture and sale of pharmaceuticals and medical devices, as well as various related businesses. The America segment is engaged in the sale of manufactured pharmaceutical products to wholesale stores in America. The firm is also engaged in the research and development of pharmaceutical products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Apr 2021
- Employees
- 3,393
- Website
- sawaigroup.holdings ↗
Leadership
Pay as last reported
- Mr. Mitsuo SawaiChairman of the Board, President, Group Chief Executive Officer, Group Chief Operating Officer, Chairman of Subsidiary, Representative Director, since 2021
- Mr. Taku NakaokaSenior Executive Officer, Group Chief Corporate Planning Officer, Group Chief Financial Officer, Group CCO, Group Chief Sustainability Officer, Director of Group Corporate Planning
- Mr. Seiji NishimuraManaging Executive Officer, Group Chief Marketing Officer
- Mr. Shoji YokotaSenior Managing Executive Officer, Group Chief Research & Development Officer, Director, since 2022
- Mr. Motohiko KimuraSenior Managing Executive Officer, President of Subsidiary
- Mr. Toshiya HasuoManaging Executive Officer, Group Chief Production Officer, President of Subsidiary
- Ms. Nobuko SugimotoManaging Executive Officer, Group Chief Intellectual Property Officer
- Mr. Toru TerashimaManaging Executive Officer, since 2021
- Mr. Toshiomi NakateSenior Executive Officer, Group Chief Quality & Safety Officer
- Mr. Toyohiro SawadaSenior Executive Officer, Group Chief Product Strategy Officer, Director of Group of Product Strategy, Group Deputy Chief Research & Development Officer
- Mr. Koji TakedaExecutive Officer, Group Chief Digital Transformation Officer, Director of Group IT
- Mr. Masayuki MitsukaIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 69
- Environment
- 91
- Social
- 99
- Governance
- 18
- Direct emissions (scope 1)
- 19,500 t
- Energy emissions (scope 2)
- 53,700 t
- Value chain emissions (scope 3)
- 231,200 t
- Women in the workforce
- 40%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sawai Group Holdings operates in the Pharmaceuticals sector with 3,393 employees in Osaka, Japan.
- The Japan segment manufactures and sells pharmaceuticals and medical devices domestically.
- The America segment distributes pharmaceutical products to wholesale stores in the United States.
Weaknesses
- The company has only two business segments, limiting diversification.
- The firm relies solely on the Japan and America segments for revenue generation.
- No mention of R&D investment levels or new product launches in the facts.
Opportunities
- Expanding the America segment into new markets within the United States.
- Increasing R&D focus on new pharmaceutical products for global markets.
- Leveraging the Japan segment's domestic presence for international partnerships.
Threats
- Dependence on the Japan segment for a significant portion of revenue.
- Competition from other pharmaceutical companies in the U.S. market.
- Regulatory changes affecting pharmaceutical sales in America.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.